戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 OQ2 and is essential for the biosynthesis of coenzyme Q10.
2 ebral cortex mitochondrial concentrations of coenzyme Q10.
3 wed that TQ is reduced more efficiently than coenzyme Q10.
4 OQ8B, a gene involved in the biosynthesis of coenzyme Q10.
5 rotein 1(FSP1)-mediated synthesis of reduced coenzyme Q10.
6 is of glutathione, phospholipids, NADPH, and coenzyme Q10.
7 nally opposing changes involving the role of Coenzyme Q10.
8 eatine, 66 received minocycline, 71 received coenzyme Q10, 71 received GPI-1485, and 138 received pla
9 P, possibly by impairing the biosynthesis of coenzyme Q10, a key component of oxidative phosphorylati
10  leronlimab, combined probiotics-prebiotics, coenzyme Q10, amygdala and insula retraining, combined L
11                               Treatment with coenzyme Q10, an essential cofactor of the electron tran
12 reased antioxidant defenses, a water-soluble coenzyme Q10 analog (Qter) was used.
13 cise duration remained unchanged in both the coenzyme Q10 and placebo groups.
14 outcome of a recent clinical trial examining coenzyme Q10 and remacemide in HD patients.
15                The combined treatment, using coenzyme Q10 and remacemide together, was more efficacio
16 ched control subjects and that the levels of coenzyme Q10 and the activities of complex I and complex
17 administration of the mitochondrial cofactor coenzyme Q10 and the NMDA antagonist remacemide.
18 , including conjugated fatty acids, sterols, coenzyme Q10, and lipophilic vitamins, such as vitamins
19 c acid) or oil-soluble (vitamin E acetate or Coenzyme Q10) antioxidants.
20                        Hereditary defects of coenzyme Q10 biosynthesis cause steroid-resistant nephro
21  we have identified 6 different mutations in coenzyme Q10 biosynthesis monooxygenase 6 (COQ6) in 13 i
22  mutations in genes that function within the coenzyme Q10 biosynthesis pathway, suggesting that SRNS
23 pplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was assoc
24 omparison of the rate of reduction of TQ and coenzyme Q10 by NQO1 showed that TQ is reduced more effi
25           They provide further evidence that coenzyme Q10 can exert neuroprotective effects that migh
26                                              Coenzyme Q10 (CoQ(10)) is an important cofactor and anti
27 ptor (suPAR) and substrate intermediates for coenzyme Q10 (CoQ(10)).
28 econd step of the final reaction sequence of Coenzyme Q10 (CoQ) biosynthesis.
29                            We focused on the coenzyme Q10 (CoQ10) biosynthesis gene Coq2, the silenci
30 lase responsible for the penultimate step of coenzyme Q10 (CoQ10) biosynthesis in mitochondria.
31 DCK3, which has been shown to participate in coenzyme Q10 (CoQ10) biosynthesis.
32  investigated whether oral administration of coenzyme Q10 (CoQ10) could attenuate 1-methyl-4-phenyl-1
33                                      Primary coenzyme Q10 (CoQ10) deficiencies are rare, clinically h
34    The authors performed sequencing of known Coenzyme Q10 (CoQ10) deficiency genes in 22 patients wit
35 irst described in 1989, our understanding of coenzyme Q10 (CoQ10) deficiency is only now coming of ag
36 showed that sulfide oxidation is impaired in Coenzyme Q10 (CoQ10) deficiency.
37                                   The use of coenzyme Q10 (CoQ10) has been increasing rapidly during
38                                              Coenzyme Q10 (CoQ10) has shown a protective effect in ne
39 rmediate involved in the biosynthesis of the coenzyme Q10 (CoQ10) headgroup in human cells.
40 ced skeletal muscle injury caused by reduced coenzyme Q10 (CoQ10) levels, which are postulated to pro
41                                              Coenzyme Q10 (CoQ10) may represent a safe therapeutic op
42     Here we report the important role of the coenzyme Q10 (CoQ10) on the activity of caspase-2 upstre
43 ence available for oral supplementation with coenzyme Q10 (CoQ10) to improve the tolerability of canc
44 ents neutral lipid peroxidation by recycling coenzyme Q10 (CoQ10) to its lipophilic antioxidant form.
45                                              Coenzyme Q10 (CoQ10) was encapsulated successfully in a
46 evented the adverse effects of alcohol while coenzyme Q10 (CoQ10) was not very effective against alco
47 stnatal supplementation with the antioxidant coenzyme Q10 (CoQ10) would prevent this programmed pheno
48 nts (dexamethasone (DX), melatonin (MEL) and coenzyme Q10 (CoQ10)) in a single formulation (DMQ-MSs)
49                                              Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial c
50                                              Coenzyme Q10 (CoQ10), an antioxidant that supports mitoc
51 he effect of long-term (6 mo) treatment with coenzyme Q10 (CoQ10), an endogenous antioxidant.
52 fied starch (OSA-ST) was used to encapsulate coenzyme Q10 (CoQ10).
53 termediate in the synthesis of ubiquinone or coenzyme Q10 (CoQ10).
54 olet, has been used for the determination of coenzyme Q10 (CoQ10).
55 pe B inhibitors (selegiline and rasagiline), coenzyme Q10, creatine, and exercise in early Parkinson'
56 are due to defects in nuclear DNA, including coenzyme Q10 deficiency and mutations in genes controlli
57                                              Coenzyme Q10 deficiency appears to be a relatively commo
58 eficiency, and one patient was found to have coenzyme Q10 deficiency due to compound heterozygous mut
59 are due to defects in nuclear DNA, including coenzyme Q10 deficiency, and mutations in genes that con
60                                              Coenzyme Q10 does not affect ejection fraction, peak oxy
61 r from the terminal Fe/S complex, N2, to the Coenzyme Q10 headgroup, docked in its binding pocket, is
62 one, coenzyme Q10, or idebenone (a synthetic coenzyme Q10 homolog), as well as inhibition of oxidativ
63 shadowed by our finding that the mobility of Coenzyme Q10 in its oxidized and reduced states, enterin
64                                    Levels of coenzyme Q10 in lymphoblastoid cells and brain tissue we
65 and antioxidant levels (alpha-tocopherol and coenzyme Q10) in brain PM during aging.
66                                 Feeding with coenzyme Q10 increased cerebral cortex concentrations in
67 ough the mean (+/-SD) serum concentration of coenzyme Q10 increased from 0.95+/-0.62 microg/mL to 2.2
68 ese results show that oral administration of coenzyme Q10 increases both brain and brain mitochondria
69                            The co-loading of Coenzyme Q10 into surfactant-stripped CyFaP (ss-CyFaP) m
70                                              Coenzyme Q10 is an essential cofactor of the electron tr
71                                              Coenzyme Q10 is commonly used to treat congestive heart
72 vidence for managing myopathic patients with coenzyme Q10 is not conclusive.
73                                              Coenzyme Q10 is the electron acceptor for complex I and
74 cronutrients involved in cardiac metabolism: coenzyme Q10, l-carnitine, thiamine, and amino acids, in
75      Patients with ADCK4 mutations had lower coenzyme Q10 levels, and coenzyme Q10 supplementation am
76                       Oral administration of coenzyme Q10 markedly attenuated striatal lesions produc
77 e binding of the electron shuttling protein, Coenzyme Q10, occurs.
78 d, cranberry extract, grapeseed extract, and coenzyme Q10 or placebo capsules as an adjunct to conser
79  We found that oral administration of either coenzyme Q10 or remacemide significantly extended surviv
80 eactive oxygen species, such as glutathione, coenzyme Q10, or idebenone (a synthetic coenzyme Q10 hom
81                                              Coenzyme Q10 (Q10) plays a critical role in cellular ene
82 ductase 1, NADH-ferrocyanide reductase, NADH-coenzyme Q10 reductase, and NADH-cytochrome c reductase)
83                      These data suggest that coenzyme Q10-related forms of SRNS and hearing loss can
84       In 12-month-old rats administration of coenzyme Q10 resulted in significant increases in cerebr
85 mutations had lower coenzyme Q10 levels, and coenzyme Q10 supplementation ameliorated renal disease i
86  Therapeutic trials of exercise training and coenzyme Q10 supplementation should continue to be offer
87 lls lacking MFN2 can be partially rescued by coenzyme Q10 supplementation, which suggests a possible
88               Some bioactive substances like coenzyme Q10, taurine, glutamine, creatine, creatinine,
89 enzoquinone (coenzyme Q1) as a surrogate for coenzyme Q10, the cofactor of this enzyme.
90 sed apoptosis that was partially reversed by coenzyme Q10 treatment.
91 ects of an antioxidant mixture of vitamin A, coenzyme Q10, vitamin C, and vitamin E were evaluated fo
92 A was more effective than ascorbic acid, and Coenzyme Q10 was more effective than vitamin E acetate.
93                                              Coenzyme Q10 was safe and well tolerated in this populat
94                   We found that the level of coenzyme Q10 was significantly lower in mitochondria fro
95 decanoic acid) and lipophilic nutraceutical (Coenzyme Q10) was investigated using a rat feeding study